Amgen (AMGN) Tops Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Nasdaq hits record high as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
- Alaska LNG shipping savings justifies billions in investment, developer says
- Citi cuts investment banking analyst program to two years - Bloomberg
- Nasdaq hits record high as investors focus on earnings
- Paramount Skydance to close WBD deal, change ticker to SKYD
- This multi-trillion stock is "cheap and getting cheaper": Morgan Stanley
Amgen (AMGN) Announces Sumission of Kyprolis sNDA to FDA, MAA to EMA
January 27, 2015 4:35 PM ESTAmgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Kyprolis (carfilzomib) for Injection to seek approval for the treatment of patients with relapsed multiple myeloma who have received at least... More



